Beijing Wandong gets domestic listing - Clone - Clone - Clone

Fifteen million "Beijing Wandong" A-shares, issued by Beijing Wandong Medical Equipment, have been publicly listed and transacted on the domestic securities market.

Fifteen million “Beijing Wandong” A-shares, issued by Beijing Wandong Medical Equipment, have been publicly listed and transacted on the domestic securities market.

Beijing Wandong specialises in the manufacture of medical equipment officially sanctioned as import replacements. Seven of its products have been recognised by the government as substitutes for imported devices.

In terms of output value, the company ranks first in medical device sector in China. Around 30% of its production is exported.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C13

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C12

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

More from